X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (30) 30
humans (24) 24
index medicus (23) 23
female (21) 21
metastatic melanoma (21) 21
middle aged (20) 20
survival (20) 20
ipilimumab (19) 19
aged (18) 18
adult (17) 17
breast cancer (12) 12
male (12) 12
chemotherapy (11) 11
follow-up (11) 11
melanoma (11) 11
cancer (10) 10
metastasis (9) 9
postmenopausal women (9) 9
care and treatment (8) 8
netherlands (8) 8
open-label (8) 8
prognosis (8) 8
therapy (8) 8
treatment outcome (8) 8
aged, 80 and over (7) 7
aromatase inhibitors (7) 7
breast neoplasms - drug therapy (7) 7
dacarbazine (7) 7
neoplasm staging (7) 7
outcomes (7) 7
registry (7) 7
safety (7) 7
tamoxifen (7) 7
vemurafenib (7) 7
analysis (6) 6
anastrozole (6) 6
clinical practice (6) 6
dabrafenib (6) 6
diagnosis (6) 6
disease-free survival (6) 6
immune-related adverse events (6) 6
kaplan-meier estimate (6) 6
letrozole (6) 6
melanoma - drug therapy (6) 6
prognostic factors (6) 6
prospective studies (6) 6
skin neoplasms - drug therapy (6) 6
aromatase inhibitor (5) 5
care (5) 5
chemotherapy, adjuvant (5) 5
exemestane (5) 5
healthcare costs (5) 5
metastatic uveal melanoma (5) 5
prognostic factor (5) 5
quality assurance (5) 5
research (5) 5
surgery (5) 5
targeted therapy (5) 5
treatment strategy (5) 5
uveal melanoma (5) 5
adjuvant endocrine therapy (4) 4
antineoplastic agents - therapeutic use (4) 4
breast neoplasms - pathology (4) 4
cancer research (4) 4
checkpoint inhibitors (4) 4
dosage and administration (4) 4
drug therapy (4) 4
hematology, oncology and palliative medicine (4) 4
map kinase inhibitors (4) 4
medical prognosis (4) 4
metastases (4) 4
multicenter (4) 4
mutation (4) 4
mutations (4) 4
patients (4) 4
phase-3 (4) 4
population-based (4) 4
risk factors (4) 4
skin and connective tissue diseases (4) 4
survival analysis (4) 4
toxicity (4) 4
adjuvant treatment (3) 3
advanced cutaneous melanoma (3) 3
blood pressure (3) 3
bone health (3) 3
bone mineral density (3) 3
breast neoplasms - mortality (3) 3
cancer patients (3) 3
clinical trials (3) 3
clinical-practice guidelines (3) 3
cohort studies (3) 3
colitis (3) 3
cross-sectional studies (3) 3
d_article_not_yet_freely_accessible (3) 3
double-blind (3) 3
drug administration schedule (3) 3
drug use (3) 3
economic burden (3) 3
efficacy (3) 3
endocrine therapy (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 943 - 953
Journal Article
International journal of cancer, ISSN 1097-0215, 2019, Volume 145, Issue 1, pp. 274 - 283
textabstractThe DATA study (NCT00301457) compared 6 and 3 years of anastrozole in postmenopausal women with hormone receptorpositive early breast cancer after... 
ovarian function recovery (OFR) | breast cancer | chemotherapy-induced ovarian function failure (CIOFF) | chemotherapy-induced amenorrhea | aromatase inhibitor | chemotherapy‐induced amenorrhea | chemotherapy‐induced ovarian function failure (CIOFF) | AMENORRHEA | LEVEL METAANALYSIS | PREMENOPAUSAL PATIENTS | EXEMESTANE | ONCOLOGY | ADJUVANT ENDOCRINE THERAPY | ESTRADIOL | LETROZOLE | BODY-MASS INDEX | POSTMENOPAUSAL WOMEN | AROMATASE INHIBITORS | Aromatase Inhibitors - administration & dosage | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Humans | Middle Aged | Proportional Hazards Models | Survival Rate | Breast Neoplasms - drug therapy | Breast Neoplasms - physiopathology | Tamoxifen - administration & dosage | Disease-Free Survival | Anastrozole - administration & dosage | Postmenopause | Female | Ovary - drug effects | Neoplasm Staging | Ovary - physiopathology | Care and treatment | Cancer patients | Relapse | Analysis | Adjuvant treatment | Breast cancer | Postmenopausal women | Tamoxifen | Cancer | Diseases | Statistical analysis | Anastrozole | Health risks | Regression analysis | Survival | Post-menopause | Confidence intervals | Time dependence | Chemotherapy | Regression models | Risk assessment | Hormone replacement therapy | Cancer Therapy and Prevention
Journal Article
International journal of cancer, ISSN 0020-7136, 2019, Volume 145, Issue 5, pp. 1325 - 1333
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 72, pp. 156 - 165
Journal Article
Journal Article
JNCI : Journal of the National Cancer Institute, ISSN 1460-2105, 2017, Volume 109, Issue 12
Journal Article